Editorial & Institutional Desk

Cell Source (CLCS) Institutional & Peer Valuation Brief: Biotechnology & Specialty Pharma vs. PCSA, CRMD, and FBIO

By the PubCo Insight Editorial Desk, edited by Brad Listermann  ·  November 18, 2026
CLCS
CLCS Cell Source, Inc.
PubCo Insight Institutional & Sector Brief: Covering Cell Source, Inc. (OTC: CLCS) following its 2026-05-14 Form 10-Q. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.

1. Balance Sheet, SEC Filing & Operating Context (2026-05-14 Form 10-Q)

Cell Source, Inc. (OTC: $CLCS, market capitalization ~$18.0M), led by Itamar Shimrat, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary SEC EDGAR XBRL records reflect capital-markets disclosure via its 2026-04-07 Form 10-K, anchoring investor diligence around balance-sheet runway and commercial execution.

CLCS price and volume
CLCS price and volume, last 90 days. Source: Yahoo Finance.

2. Institutional & Family Office Peer Comparison ($PCSA, $CRMD, and $FBIO)

Across our institutional and active small-cap allocator screens benchmarking $CLCS against $PCSA, $CRMD, and $FBIO, three factors stand out:

Free Public-Company AI & Investor Search Visibility Report

Cell Source, Inc. ($CLCS) Investor Search & Diligence Audit

38 / 100
Visibility Score

Why This Costs $CLCS Buyers & Volume: Before retail traders, family offices, or microcap funds buy a single share of $CLCS, over 70% run a 30-second search across ChatGPT, Perplexity Finance, and TradingView. When prospective investors cannot find clean, current SEC figures or hit stale third-party data, they skip out, do not invest, and buy a peer instead. Here is what investors currently see when they search Cell Source, Inc.:

Investor Search SurfaceScoreWhere Prospective Buyers Are Dropping Off
ChatGPT & OpenAI Search35/100Missing root /llms.txt manifest and structured IR schema; surfaces stale baseline summaries instead of recent $CLCS SEC filings.
Perplexity Finance & Citations42/100Pulls fragmented quote-scraper snippets instead of verified SEC EDGAR operating milestones and peer valuation context for $CLCS.
TradingView, FactSet & Sector Screens37/100$CLCS is omitted from AI discovery screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization due to unindexed entity and FAQPage metadata.
Turnkey Cleanup & Investor Distribution Package for Cell Source, Inc.: Pulse IR fixes how ChatGPT, Perplexity, TradingView, FactSet, Wikidata, and your IR page display $CLCS directly from your SEC filings (requiring zero hours from your team), and then distributes your verified story to our 22,361 active microcap traders and 165 family offices and funds tracking your sector. To claim this report and review our turnkey package with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.

Primary sources (SEC EDGAR)

CLCS Primary SEC EDGAR Filings: https://www.sec.gov/edgar/browse/?CIK=0001569340
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.
Investor relations · CLCS
Is this how AI describes Cell Source, Inc.?
This page is the public, source-linked snapshot that investors, brokers, and AI assistants pull for CLCS: EDGAR filings and recent news, no editor, no spin. When an AI engine or a financial terminal shows stale, misclassified, or missing data for your ticker, that is the first thing investors see. Pulse IR runs a free 24-hour audit of how ChatGPT, Perplexity, Google, and the major terminals currently represent CLCS, and can correct it.
Get the free AI visibility audit
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
See all CLCS filings and data  ·  Uplist Radar  ·  Catalyst Radar  ·  Pulse IR Capital & Institutional Desk